Segundo Gonzalez

Segundo Gonzalez

Company: Universidad de Oviedo

Job title: Leader


LAG-3 Blockade with Relatlimab Restores Anti Leukemic Immune Response in Chronic Lymphocytic Leukemia 9:00 am

• Chronic lymphocytic leukemia (CLL) is one of the cancers in which LAG-3 has more clinical influence • Relatlimab restored NK cell and T-cell mediated responses in CLL ex vivo • The immunomodulatory drug lenalidomide boost relatlimab activityRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.